Delivering the Full Promise of RNA-Targeted Therapeutics

Ribometrix is leading a new drug-discovery paradigm: small molecules that correct the production of disease-causing proteins by targeting their encoding RNAs.

Ribometrix Lab

The Ribometrix Vision

The Next Big Biological Breakthrough

Unlike most conventional therapeutic pipelines which use the power of small molecules to target proteins, or more modern pipelines grappling with the limitations of oligonucleotides to tap the huge potential of targeting RNAs, we are combining the best of both worlds by developing small molecule drugs that directly target cellular RNAs to thereby correct the levels of their encoded, disease-causing proteins.

Create the Future With Us

We’ve teamed up with strategic partners to help us advance the new therapeutics frontier of direct RNA targeting using small molecules.

About Ribometrix

Headquartered in the heart of North Carolina’s Research Triangle Park, we’ve built the leading industry platform for discovering and developing RNA-targeting small molecule therapeutics.

Ribometrix team meeting

Experts Pioneering a Brand New Field

Our team of RNA experts and drug discovery specialists brings decades of cross-disciplinary experience towards tackling exciting challenges to realize a powerful promise.

Ribometix team
Careers

Enjoy a Life-Changing Career at Ribometrix

Cutting-edge technology. Game-changing medical breakthroughs. Working alongside the most passionate scientific leaders in RNA biology. Ribometrix is a unique opportunity to trailblaze the next frontier in drug discovery.

“Targeting RNA is a potentially powerful new approach for developing small molecule therapeutics, and Ribometrix has developed an innovative technology for the accelerated discovery of selective candidates in this new space.”
Mark Bunnage, Senior Vice President and Global Head of Research 

Vertex Pharmaceuticals Incorporated
“Through extraordinary commitment and scientific rigor, Ribometrix is now on the verge of opening a new horizon in drug discovery — RNA modulation by small molecules.”
Mike Clayman, Chairman of the Board
Ribometrix

Connect With Us

For more information, or interest in partnerships, please fill out the form.

This field is for validation purposes and should be left unchanged.